WCN26-7623 CLAUDIN-1 INHIBITOR AMELIORATES DIABETIC KIDNEY DISEASE BY SUPPRESSING SRC/AKT/MTOR SIGNALING PATHWAY

Read full text Summarise with VIRAT
Authors: Kazuhiko Fukushima, Kenji Tsuji, Hiroyuki Nakanoh, Naruhiko Uchida, Shinji Kitamura, Jun Wada
Cited by: 0
References: 29

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Recent studies have reported that claudin-1 (CLDN1), which is reactively expressed in malignant tumors and inflammatory diseases, plays an important role in disease progression. In diabetic kidney disease, upregulated expression of CLDN1 in podocytes has also been shown to contribute to disease progression. However, it remains unclear whether CLDN1 itself could be a therapeutic target in diabetic kidney disease. In this study, we investigated whether the CLDN1 inhibitor PDS-0330 could ameliorate diabetic kidney disease.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Renal Diseases and Glomerulopathies Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104642–104642
Publication date
25 March 2026
Language
EN